Symbols / ALLR $1.28 +1.59%
ALLR Chart
About
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 20.58M |
| Enterprise Value | 4.73M | Income | -15.31M | Sales | — |
| Book/sh | 0.74 | Cash/sh | 1.07 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6 | IPO | — |
| P/E | 0.14 | Forward P/E | -1.32 | PEG | — |
| P/S | — | P/B | 1.72 | P/C | — |
| EV/EBITDA | -0.28 | EV/Sales | — | Quick Ratio | 2.11 |
| Current Ratio | 2.33 | Debt/Eq | 11.57 | LT Debt/Eq | — |
| EPS (ttm) | 9.11 | EPS next Y | -0.97 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 09:00 | ROA | -51.62% |
| ROE | -122.61% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 16.08M |
| Shs Float | 15.79M | Short Float | 1.42% | Short Ratio | 1.14 |
| Short Interest | — | 52W High | 2.35 | 52W Low | 0.61 |
| Beta | 0.20 | Avg Volume | 179.01K | Volume | 148.69K |
| Target Price | $9.50 | Recom | None | Prev Close | $1.26 |
| Price | $1.28 | Change | 1.59% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.50
Mean price target
2. Current target
$1.28
Latest analyst target
3. DCF / Fair value
$-11.74
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.28
Low
$9.50
High
$9.50
Mean
$9.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-09 | main | Ascendiant Capital | Buy → Buy | $10 |
| 2025-09-26 | main | Ascendiant Capital | Buy → Buy | $9 |
| 2025-07-28 | init | Ascendiant Capital | — → Buy | $9 |
- Ovarian cancer drug keeping patients 30+ months gets $20M boost - Stock Titan Fri, 06 Mar 2026 08
- Allarity Therapeutics Signs Common Stock Purchase Agreement With Tumim Stone Capital - TradingView hu, 29 Jan 2026 08
- Allarity Therapeutics stock soars after FDA Fast Track designation - Investing.com ue, 26 Aug 2025 07
- Allarity Therapeutics (NASDAQ: ALLR) closes $20M debt to fund trials - Stock Titan Mon, 09 Mar 2026 13
- Allarity Therapeutics Secures $20 Million Structured Note Financing - TipRanks Fri, 06 Mar 2026 13
- Why Did Allarity Therapeutics Stock Double In Value Today? - Stocktwits ue, 26 Aug 2025 17
- ALLR Forecast — Price Prediction for 2026. Should I Buy ALLR? - Intellectia AI ue, 03 Jun 2025 09
- Allarity Therapeutics Raises Amidst Promising Developments - StocksToTrade ue, 26 Aug 2025 07
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga Wed, 11 Feb 2026 08
- Allarity Therapeutics (ALLR) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $ALLR - MarketBeat hu, 10 Jul 2025 05
- Allarity Therapeutics Secures Flexible Equity Financing Facility - TipRanks hu, 29 Jan 2026 08
- FDA Fast-Tracks Promising Ovarian Cancer Drug: Allarity's Stenoparib Shows 22-Month Patient Benefits - Stock Titan ue, 26 Aug 2025 07
- Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization - Yahoo Finance UK ue, 15 Jul 2025 07
- Latest Developments in Allarity Therapeutics - timothysykes.com ue, 26 Aug 2025 07
- Lawsuit NOTICE: Investors Who Lost More Than $100,000 With Allarity Therapeutics, Inc. (NASDAQ: ALLR) Shares Should Contact the Shareholders Foundation - Newswire.com Wed, 25 Sep 2024 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 133333 | — | — | Stock Award(Grant) at price 0.00 per share. | GRAFF JEREMY R. | President | — | 2026-01-07 00:00:00 | D |
| 1 | 39494 | nan | — | — | GRAFF JEREMY R. | President | — | 2025-09-30 00:00:00 | D |
| 2 | 396734 | — | — | Stock Award(Grant) at price 0.00 per share. | JENSEN THOMAS | Chief Executive Officer | — | 2025-01-22 00:00:00 | D |
| 3 | 144441 | — | — | Stock Award(Grant) at price 0.00 per share. | GRAFF JEREMY R. | Officer | — | 2025-01-22 00:00:00 | D |
| 4 | 29496 | — | — | Stock Award(Grant) at price 0.00 per share. | EPSHINSKY ALEXANDER | Chief Financial Officer | — | 2025-01-22 00:00:00 | D |
| 5 | 118483 | 249999.0 | — | Stock Award(Grant) at price 2.11 per share. | GRAFF JEREMY R. | President | — | 2024-09-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -110.77K | 1.34M | -42.74K | 675.54K |
| TaxRateForCalcs | 0.02 | 0.21 | 0.09 | 0.27 |
| NormalizedEBITDA | -17.00M | -17.66M | -16.80M | -28.27M |
| TotalUnusualItems | -7.24M | 6.38M | -494.00K | 2.50M |
| TotalUnusualItemsExcludingGoodwill | -7.24M | 6.38M | -494.00K | 2.50M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -24.52M | -11.90M | -16.06M | -26.65M |
| ReconciledDepreciation | 9.00K | 37.00K | 60.00K | 106.00K |
| EBITDA | -24.23M | -11.28M | -17.30M | -25.77M |
| EBIT | -24.24M | -11.32M | -17.36M | -25.88M |
| NetInterestIncome | -120.00K | -476.00K | -193.00K | -1.99M |
| InterestExpense | 653.00K | 498.00K | 223.00K | 640.00K |
| InterestIncome | 533.00K | 22.00K | 30.00K | 0.00 |
| NormalizedIncome | -17.39M | -16.94M | -15.61M | -28.47M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -24.52M | -11.90M | -16.06M | -26.65M |
| TotalExpenses | 17.54M | 17.13M | 16.89M | 26.56M |
| TotalOperatingIncomeAsReported | -27.24M | -17.13M | -34.46M | -26.56M |
| DilutedAverageShares | 1.61M | 3.38K | 662.00 | 337.00 |
| BasicAverageShares | 1.61M | 3.38K | 662.00 | 337.00 |
| DilutedEPS | -15.65 | -6.03K | -31.80K | -79.07K |
| BasicEPS | -15.65 | -6.03K | -31.80K | -79.07K |
| DilutedNIAvailtoComStockholders | -25.15M | -20.42M | -21.05M | -26.65M |
| NetIncomeCommonStockholders | -25.15M | -20.42M | -21.05M | -26.65M |
| PreferredStockDividends | 639.00K | 8.52M | 4.99M | |
| NetIncome | -24.52M | -11.90M | -16.06M | -26.65M |
| MinorityInterests | 0.00 | |||
| NetIncomeIncludingNoncontrollingInterests | -24.52M | -11.90M | -16.06M | -26.65M |
| NetIncomeContinuousOperations | -24.52M | -11.90M | -16.06M | -26.65M |
| TaxProvision | -381.00K | 83.00K | -1.52M | 133.00K |
| PretaxIncome | -24.90M | -11.82M | -17.58M | -26.52M |
| OtherIncomeExpense | -7.24M | 5.79M | -494.00K | 2.03M |
| OtherNonOperatingIncomeExpenses | -591.00K | -474.00K | ||
| SpecialIncomeCharges | -9.70M | 0.00 | -16.59M | 1.00M |
| GainOnSaleOfPPE | 0.00 | 1.78M | 1.00M | |
| OtherSpecialCharges | 800.00K | 141.00K | ||
| ImpairmentOfCapitalAssets | 9.70M | 0.00 | 17.57M | 0.00 |
| GainOnSaleOfSecurity | 2.46M | 6.38M | 16.10M | 1.50M |
| NetNonOperatingInterestIncomeExpense | -120.00K | -476.00K | -193.00K | -1.99M |
| TotalOtherFinanceCost | 1.35M | |||
| InterestExpenseNonOperating | 653.00K | 498.00K | 223.00K | 640.00K |
| InterestIncomeNonOperating | 533.00K | 22.00K | 30.00K | 0.00 |
| OperatingIncome | -17.54M | -17.13M | -16.89M | -26.56M |
| OperatingExpense | 17.54M | 17.13M | 16.89M | 26.56M |
| ResearchAndDevelopment | 6.10M | 7.10M | 6.93M | 14.20M |
| SellingGeneralAndAdministration | 11.44M | 10.03M | 9.96M | 12.36M |
| GeneralAndAdministrativeExpense | 11.44M | 10.03M | 9.96M | 12.36M |
| OtherGandA | 11.44M | 10.03M | 9.96M | 12.36M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 7.30M | 9.81K | 662.00 | 337.00 |
| ShareIssued | 7.30M | 9.81K | 662.00 | 337.00 |
| NetDebt | 1.13M | 1.70M | ||
| TotalDebt | 1.35M | 1.30M | 3.73M | 1.09M |
| TangibleBookValue | 11.81M | -14.36M | -9.66M | -9.98M |
| InvestedCapital | 13.16M | -3.19M | 3.61M | 19.13M |
| WorkingCapital | 11.50M | -12.20M | -6.25M | 685.00K |
| NetTangibleAssets | 11.81M | -12.62M | -7.66M | -9.35M |
| CapitalLeaseObligations | 0.00 | 8.00K | 107.00K | |
| CommonStockEquity | 11.81M | -4.49M | -113.00K | 18.15M |
| PreferredStockEquity | 1.74M | 2.00M | 632.00K | |
| TotalCapitalization | 11.81M | -2.75M | 2.97M | 19.76M |
| TotalEquityGrossMinorityInterest | 11.81M | -2.75M | 1.89M | 18.78M |
| StockholdersEquity | 11.81M | -2.75M | 1.89M | 18.78M |
| GainsLossesNotAffectingRetainedEarnings | -354.00K | -411.00K | -721.00K | -600.00K |
| OtherEquityAdjustments | -354.00K | -411.00K | -721.00K | -600.00K |
| RetainedEarnings | -118.97M | -94.45M | -82.55M | -66.49M |
| AdditionalPaidInCapital | 131.13M | 90.37M | 83.16M | 85.24M |
| CapitalStock | 1.00K | 1.74M | 2.00M | 633.00K |
| CommonStock | 1.00K | 0.00 | 0.00 | 1.00K |
| PreferredStock | 0.00 | 1.74M | 2.00M | 632.00K |
| TotalLiabilitiesNetMinorityInterest | 10.84M | 14.61M | 12.65M | 30.85M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 446.00K | 1.43M | 10.13M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 0.00 | 632.00K | |
| DerivativeProductLiabilities | 7.18M | |||
| NonCurrentDeferredLiabilities | 0.00 | 446.00K | 349.00K | 1.96M |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 446.00K | 349.00K | 1.96M |
| LongTermDebtAndCapitalLeaseObligation | 1.08M | 988.00K | ||
| LongTermCapitalLeaseObligation | 0.00 | 9.00K | ||
| LongTermDebt | 1.08M | 979.00K | ||
| CurrentLiabilities | 10.84M | 14.17M | 11.22M | 20.72M |
| OtherCurrentLiabilities | 1.00K | 3.08M | 374.00K | 11.27M |
| CurrentDebtAndCapitalLeaseObligation | 1.35M | 1.30M | 2.65M | 98.00K |
| CurrentCapitalLeaseObligation | 0.00 | 8.00K | 98.00K | |
| CurrentDebt | 1.35M | 1.30M | 2.64M | |
| OtherCurrentBorrowings | 1.35M | 1.30M | 2.64M | |
| LineOfCredit | 0.00 | |||
| CurrentNotesPayable | 0.00 | 2.64M | ||
| PayablesAndAccruedExpenses | 9.49M | 9.78M | 8.20M | 9.35M |
| CurrentAccruedExpenses | 5.23M | 1.31M | 1.90M | 8.59M |
| InterestPayable | 281.00K | 101.00K | 0.00 | |
| Payables | 4.26M | 8.47M | 6.29M | 758.00K |
| TotalTaxPayable | 74.00K | 59.00K | 41.00K | 60.00K |
| IncomeTaxPayable | 74.00K | 59.00K | 41.00K | 60.00K |
| AccountsPayable | 4.18M | 8.42M | 6.25M | 698.00K |
| TotalAssets | 22.65M | 11.86M | 14.54M | 49.63M |
| TotalNonCurrentAssets | 309.00K | 9.89M | 9.58M | 28.23M |
| InvestmentsAndAdvances | 350.00K | |||
| InvestmentinFinancialAssets | 350.00K | |||
| AvailableForSaleSecurities | 350.00K | |||
| GoodwillAndOtherIntangibleAssets | 0.00 | 9.87M | 9.55M | 28.14M |
| OtherIntangibleAssets | 9.87M | 9.55M | 28.14M | |
| NetPPE | 309.00K | 20.00K | 27.00K | 94.00K |
| AccumulatedDepreciation | -328.00K | |||
| GrossPPE | 309.00K | 20.00K | 27.00K | 94.00K |
| OtherProperties | 309.00K | 20.00K | 27.00K | 94.00K |
| CurrentAssets | 22.34M | 1.97M | 4.97M | 21.40M |
| CurrentDeferredAssets | 0.00 | 1.34M | 0.00 | |
| PrepaidAssets | 579.00K | 859.00K | 727.00K | 154.00K |
| Receivables | 2.23M | 946.00K | 871.00K | 1.34M |
| TaxesReceivable | 813.00K | 946.00K | 871.00K | 1.34M |
| AccountsReceivable | 1.42M | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 19.53M | 166.00K | 2.03M | 19.91M |
| OtherShortTermInvestments | 0.00 | 350.00K | ||
| CashAndCashEquivalents | 19.53M | 166.00K | 2.03M | 19.55M |
| CashFinancial | 19.53M | 166.00K | 2.03M | 19.55M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -17.65M | -12.74M | -16.84M | -14.89M |
| RepurchaseOfCapitalStock | -3.50M | -6.65M | -1.51M | 0.00 |
| RepaymentOfDebt | -1.34M | -3.70M | 0.00 | -2.94M |
| IssuanceOfDebt | 1.34M | 1.05M | 1.00M | 4.00M |
| IssuanceOfCapitalStock | 40.29M | 18.05M | 0.00 | 32.12M |
| CapitalExpenditure | -298.00K | -18.00K | ||
| InterestPaidSupplementalData | 34.00K | 85.00K | 262.00K | |
| IncomeTaxPaidSupplementalData | 6.00K | 12.00K | 118.00K | |
| EndCashPosition | 19.53M | 166.00K | 2.03M | 19.55M |
| BeginningCashPosition | 166.00K | 2.03M | 19.55M | 298.00K |
| EffectOfExchangeRateChanges | 225.00K | -113.00K | -189.00K | -680.00K |
| ChangesInCash | 19.14M | -1.75M | -17.34M | 19.94M |
| FinancingCashFlow | 36.79M | 10.99M | -1.31M | 33.82M |
| CashFlowFromContinuingFinancingActivities | 36.79M | 10.99M | -1.31M | 33.82M |
| NetOtherFinancingCharges | -800.00K | -2.04M | ||
| ProceedsFromStockOptionExercised | 0.00 | 2.24M | 0.00 | 2.77M |
| NetPreferredStockIssuance | -562.00K | -5.49M | -1.51M | 0.00 |
| PreferredStockPayments | -3.50M | -6.65M | -1.51M | 0.00 |
| PreferredStockIssuance | 2.94M | 1.16M | 0.00 | |
| NetCommonStockIssuance | 37.35M | 16.89M | 0.00 | 32.12M |
| CommonStockIssuance | 37.35M | 16.89M | 0.00 | 32.12M |
| NetIssuancePaymentsOfDebt | 0.00 | -2.65M | 1.00M | 969.00K |
| NetShortTermDebtIssuance | 0.00 | -84.00K | ||
| NetLongTermDebtIssuance | 0.00 | -2.65M | 1.00M | 1.05M |
| LongTermDebtPayments | -1.34M | -3.70M | 0.00 | -2.94M |
| LongTermDebtIssuance | 1.34M | 1.05M | 1.00M | 4.00M |
| InvestingCashFlow | -298.00K | 0.00 | 791.00K | 1.00M |
| CashFlowFromContinuingInvestingActivities | -298.00K | 0.00 | 791.00K | 1.00M |
| NetIntangiblesPurchaseAndSale | 0.00 | 809.00K | 1.00M | |
| SaleOfIntangibles | 0.00 | 809.00K | 1.00M | |
| NetPPEPurchaseAndSale | -298.00K | 0.00 | -18.00K | 0.00 |
| PurchaseOfPPE | -298.00K | 0.00 | -18.00K | 0.00 |
| OperatingCashFlow | -17.35M | -12.74M | -16.82M | -14.89M |
| CashFlowFromContinuingOperatingActivities | -17.35M | -12.74M | -16.82M | -14.89M |
| ChangeInWorkingCapital | 63.00K | 3.35M | -328.00K | 5.57M |
| ChangeInOtherWorkingCapital | 207.00K | |||
| ChangeInOtherCurrentLiabilities | 0.00 | -8.00K | -99.00K | -124.00K |
| ChangeInOtherCurrentAssets | 94.00K | 1.35M | -1.08M | -330.00K |
| ChangeInPayablesAndAccruedExpense | -557.00K | 2.23M | 1.47M | 5.89M |
| ChangeInAccruedExpense | 3.54M | 43.00K | -4.72M | 7.20M |
| ChangeInPayable | -4.09M | 2.18M | 6.19M | -1.30M |
| ChangeInAccountPayable | -4.11M | 2.17M | 6.21M | -1.31M |
| ChangeInTaxPayable | 15.00K | 18.00K | -19.00K | 8.00K |
| ChangeInIncomeTaxPayable | 15.00K | 18.00K | -19.00K | 8.00K |
| ChangeInPrepaidAssets | 274.00K | -190.00K | -618.00K | 130.00K |
| ChangeInReceivables | 45.00K | -26.00K | 0.00 | 0.00 |
| ChangesInAccountReceivables | 0.00 | |||
| OtherNonCashItems | 566.00K | 1.57M | 138.00K | 2.06M |
| StockBasedCompensation | 71.00K | -71.00K | 1.75M | 6.37M |
| AssetImpairmentCharge | 9.70M | 0.00 | 17.57M | 0.00 |
| DeferredTax | -446.00K | 97.00K | -1.61M | 20.00K |
| DeferredIncomeTax | -446.00K | 97.00K | -1.61M | 20.00K |
| DepreciationAmortizationDepletion | 9.00K | 37.00K | 60.00K | 106.00K |
| DepreciationAndAmortization | 9.00K | 37.00K | 60.00K | 106.00K |
| OperatingGainsLosses | -2.80M | -5.83M | -18.34M | -2.36M |
| GainLossOnInvestmentSecurities | -2.68M | -5.65M | -17.01M | -1.59M |
| NetForeignCurrencyExchangeGainLoss | -126.00K | -179.00K | 450.00K | 95.00K |
| GainLossOnSaleOfPPE | 0.00 | -1.78M | -1.00M | |
| NetIncomeFromContinuingOperations | -24.52M | -11.90M | -16.06M | -26.65M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ALLR
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|